Adicet Bio, Inc.: insider trades · United States · SEC (Form 4)

About Adicet Bio, Inc.

Adicet Bio, Inc. (ticker: ACET) is a clinical-stage biotechnology company listed on the Nasdaq market in the United States (United States). For international equity investors, the name fits the profile of a high-risk, high-upside biopharma story built around an off-the-shelf allogeneic cell therapy platform based on gamma delta T cells. The company is focused on developing engineered T-cell therapies for autoimmune diseases and cancer, using CAR-enabled products designed to improve targeting, tissue homing and drug exposure. Its lead program is prula-cel (formerly ADI-001), a first-in-class allogeneic gamma delta T-cell therapy targeting CD20 and being advanced primarily in autoimmune indications such as lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), with additional expansion into other autoimmune settings. Adicet is also developing ADI-212, a next-generation gene-edited and armored candidate aimed at metastatic castration-resistant prostate cancer (mCRPC). The company was founded in 2014 by Aya Jakobovits, with OrbiMed as an early backer, and its current public-company structure was shaped by the September 2020 merger with resTORbio. That transaction kept Adicet in the public markets while allowing it to sharpen its strategic focus on cell therapy. Today, Adicet operates with offices in Redwood City and Boston, and also maintains a presence in Shanghai. That footprint reflects a small but globally minded R&D organization rather than a commercial-stage footprint. The business remains clearly clinical and pre-commercial, so valuation is driven primarily by trial design, data quality, regulatory interactions and capital runway rather than near-term sales. In competitive terms, Adicet occupies a niche but potentially differentiated segment of immunotherapy. Its gamma delta platform is designed to offer an allogeneic, scalable approach that may improve tolerability and make cell therapy more accessible across a broader set of diseases. That said, the company competes with much better capitalized biotech peers in autoimmune disease, hematology and solid tumors, making execution and data readouts essential. The key investment debate is whether its biology can translate into repeatable clinical signals strong enough to justify later-stage development and eventual partnering or commercialization. Recent developments have been important. In early 2026, Adicet said enrollment in the Phase 1 autoimmune study of prula-cel had more than doubled to over 20 patients, and management guided to multiple clinical updates during 2026. The company also reported alignment with the FDA to enable outpatient dosing for certain LN and SLE patients, and it continued advancing ADI-212 toward a regulatory filing. Financially, Adicet raised capital in 2025, extending its cash runway into the second half of 2027, which is a meaningful consideration for investors assessing dilution risk and clinical optionality on Nasdaq.